Loading...
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis share driver mutations that either activate the thrombopoietin receptor, MPL, or indirectly activate it through mutations in the gene for JAK2, its cognate tyrosine kinase. Paradoxically, although...
Na minha lista:
| Udgivet i: | Front Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7987816/ https://ncbi.nlm.nih.gov/pubmed/33777803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.641613 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|